BillionToOne Files S-1, Targeting Nasdaq Amidst Rapid Revenue Growth

Ticker: BLLN · Form: S-1 · Filed: Oct 7, 2025 · CIK: 2070849

Sentiment: mixed

Topics: Precision Diagnostics, Biotechnology, IPO, Genetic Testing, Oncology, Prenatal Screening, Dual-Class Stock, High Growth

TL;DR

**BillionToOne is a high-growth diagnostics play with impressive revenue and margin expansion, but the co-founders' iron grip on voting power is a red flag for public shareholders.**

AI Summary

BillionToOne, Inc. (BLLN) is filing an S-1 for its initial public offering, aiming to list on the Nasdaq Global Select Market. The company, a precision diagnostics firm, reported an annualized revenue run-rate (ARR) of $265 million as of Q2 2025, representing an 86% year-over-year growth. Its last twelve months (LTM) revenue reached $209 million as of June 30, 2025, with a remarkable 167% CAGR from 2021 to 2024. BillionToOne is nearing profitability, with a Q2 2025 EBITDA of $0.1 million and a net loss of ($0.2 million), significantly improving from a ($42 million) net loss in 2024. The company's gross profit margin stood at 65% in H1 2025, a 14 percentage point increase year-over-year. Key risks include the dual-class stock structure, where Co-Founders Oguzhan Atay and David Tsao will control approximately 100% of voting power, and the reliance on a $100 billion estimated US annual market opportunity, half of which is in early detection, an area where they have not yet launched products. The strategic outlook emphasizes expanding their diagnostic platform, which has already processed over 1 million tests since launch, into new areas like early cancer detection.

Why It Matters

BillionToOne's S-1 filing signals a significant entry into the public market for a company poised to disrupt precision diagnostics with its 'one molecule at a time' technology. For investors, the dual-class stock structure, granting co-founders Oguzhan Atay and David Tsao significant control, presents a governance risk despite the impressive 167% revenue CAGR. Employees and customers could see benefits from increased capital for R&D and market expansion, potentially leading to more advanced diagnostic tests like UNITY Fetal Risk™ Screen and Northstar Select®. The broader market will watch how BLLN competes with established diagnostic giants, especially as it targets a $100 billion US annual market opportunity, half of which is currently untapped by the company.

Risk Assessment

Risk Level: high — The risk level is high due to the dual-class stock structure, where Co-Founders Oguzhan Atay and David Tsao will beneficially own 100% of Class B common stock, granting them approximately 100% of the voting power post-IPO. This concentration of control significantly limits public shareholders' influence. Additionally, the company's estimated $100 billion US annual market opportunity includes a substantial portion for early detection, an area where BillionToOne has not yet begun specific product development or commercial sales, introducing market execution risk.

Analyst Insight

Investors should carefully evaluate the implications of the dual-class share structure on corporate governance and shareholder rights before investing. While the company's strong revenue growth (167% CAGR 2021-2024) and improving profitability are attractive, consider the execution risk associated with expanding into new, unaddressed market segments like early detection, which constitutes half of their projected $100 billion market opportunity.

Financial Highlights

debt To Equity
N/A
revenue
$209M
operating Margin
N/A
total Assets
N/A
total Debt
N/A
net Income
($0.2M)
eps
N/A
gross Margin
65%
cash Position
N/A
revenue Growth
+167%

Executive Compensation

NameTitleTotal Compensation
Oguzhan AtayCo-Founder, Chief Executive Officer and Chairman$375,000
David TsaoCo-Founder and Chief Technology Officer$375,000

Key Numbers

Key Players & Entities

FAQ

What is BillionToOne's current revenue and growth rate?

BillionToOne reported an annualized revenue run-rate (ARR) of $265 million as of Q2 2025, reflecting an 86% year-over-year revenue growth compared to Q2 2024. Their last twelve months (LTM) revenue was $209 million as of June 30, 2025, with a 167% CAGR from 2021 to 2024.

Who are the co-founders of BillionToOne and what is their control over the company?

The co-founders of BillionToOne are Oguzhan Atay, Chief Executive Officer, and David Tsao, Chief Technology Officer. Following the IPO, they will beneficially own 100% of the outstanding Class B common stock, which carries 15 votes per share, giving them approximately 100% of the voting power.

What are the key risks for investors in BillionToOne's IPO?

A primary risk is the dual-class stock structure, which grants the co-founders significant voting control, limiting public shareholder influence. Another risk is the reliance on a $100 billion estimated US annual market opportunity, with half of it in early detection, an area where the company has not yet launched specific products.

What is BillionToOne's profitability outlook?

BillionToOne is showing emerging profitability, with a Q2 2025 EBITDA of $0.1 million and a net loss of ($0.2 million). This is a significant improvement from a net loss of ($42 million) in 2024 and ($83 million) in 2023.

What types of diagnostic tests does BillionToOne offer?

BillionToOne offers prenatal tests like UNITY Fetal Risk™ Screen, which detects risks for severe diseases early in pregnancy, and oncology tests such as Northstar Select®, which identifies actionable cancer variants and monitors treatment efficacy.

How many tests has BillionToOne processed since its launch?

BillionToOne has processed over 1 million tests since its launch, with 508,000 LTM tests accessioned as of June 30, 2025, representing a 51% year-over-year growth in tests accessioned.

What is BillionToOne's gross profit margin?

BillionToOne achieved a 65% gross profit margin in H1 2025, which represents a 14 percentage point year-over-year increase, indicating improved cost efficiency in its operations.

What is the estimated total addressable market for BillionToOne?

BillionToOne estimates its US annual market opportunity to be $100 billion. However, half of this market opportunity is in early detection, an area where the company has not yet begun specific product development or commercial sales.

What is the proposed stock ticker and listing exchange for BillionToOne?

BillionToOne has applied to list its Class A common stock on the Nasdaq Global Select Market under the symbol "BLLN."

What is the significance of BillionToOne's technology?

BillionToOne's technology is designed to detect disease one molecule at a time, pushing beyond current diagnostic limitations. Their platform can detect a single DNA letter of a single DNA molecule among three billion others, enabling highly precise prenatal and oncology tests.

Risk Factors

Industry Context

BillionToOne operates in the precision diagnostics market, a rapidly growing sector driven by advancements in genomic sequencing and data analytics. The company competes with established players and emerging startups focused on early disease detection and personalized medicine. Key trends include the increasing demand for non-invasive testing and the integration of AI in diagnostic interpretation.

Regulatory Implications

The diagnostic industry is subject to stringent regulatory oversight, primarily from the FDA in the US. BillionToOne's success hinges on obtaining necessary approvals for its novel diagnostic tests. Any delays or failures in the regulatory process for new product launches, especially in areas like early cancer detection, pose a significant risk.

What Investors Should Do

  1. Monitor progress on new product launches, particularly in early cancer detection.
  2. Evaluate the company's ability to scale operations and maintain gross margins.
  3. Assess the long-term implications of the dual-class stock structure.
  4. Track the company's path to profitability and cash burn rate.

Glossary

Annualized Revenue Run-rate (ARR)
A projection of a company's total revenue for the next 12 months, based on its current revenue performance. (Indicates BillionToOne's current revenue momentum, showing a strong $265 million as of Q2 2025.)
CAGR
Compound Annual Growth Rate, a measure of the average annual growth rate of an investment over a specified period of time longer than one year. (Highlights BillionToOne's explosive historical revenue growth of 167% from 2021 to 2024.)
EBITDA
Earnings Before Interest, Taxes, Depreciation, and Amortization, a measure of a company's operating performance. (Shows BillionToOne is nearing profitability, with a positive $0.1 million in Q2 2025.)
Gross Profit Margin
The percentage of revenue that exceeds the cost of goods sold. (Indicates improved operational efficiency for BillionToOne, reaching 65% in H1 2025.)
LTM
Last Twelve Months, referring to the most recent 12-month period for which financial data is available. (Provides a current snapshot of BillionToOne's revenue ($209 million) and test volume (508K) as of June 30, 2025.)
Dual-class stock structure
A corporate structure where a company issues different classes of stock with different voting rights. (A key risk factor for BillionToOne, as it concentrates voting power with the co-founders.)

Year-Over-Year Comparison

This is the initial S-1 filing, so a direct comparison to a previous filing is not applicable. However, the company demonstrates significant growth, with LTM revenue of $209 million and an 86% year-over-year increase in ARR to $265 million as of Q2 2025. Gross margins have improved to 65%, and the company is nearing profitability with a Q2 2025 net loss of ($0.2 million), a substantial improvement from the prior year. New risks related to the dual-class stock structure and reliance on unlaunched products are highlighted.

Filing Stats: 4,679 words · 19 min read · ~16 pages · Grade level 11.7 · Accepted 2025-10-07 17:30:01

Key Financial Figures

Filing Documents

Risk factors

Risk factors 22 Special note regarding forward-looking statements 79 Market, industry and other data 81

Use of proceeds

Use of proceeds 82 Dividend policy 83 Capitalization 84

Management's discussion and analysis of financial condition and results of operations

Management's discussion and analysis of financial condition and results of operations 90

Business

Business 128 Management 196

Executive compensation

Executive compensation 203 Certain relationships and related party transactions 214 Principal stockholders 219

Description of capital stock

Description of capital stock 222 Shares eligible for future sale 229 Material U.S. federal income tax consequences to non-U.S. holders of our Class A common stock 232

Underwriting

Underwriting 237 Legal matters 251 Experts 251 Where you can find additional information 251 Index to financial statements F-1 Through and including , 2025 (the 25th day after the date of this prospectus), all dealers that effect transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers' obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions. We have not, and the underwriters have not, authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectus prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares of Class A common stock offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of shares of our Class A common stock. Our business, financial condition, results of operations and prospects may have changed since that date. Table of Contents For investors outside the United States: Neither we nor any of the underwriters have taken any action that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons who have come into possession of this prospectus in a jurisdiction outside the United States are required to inform themselves about and to observe any restrictions relating to this offering and the distribution of this prospectus. Table of Contents Letter from Our Co-

View Full Filing

View this S-1 filing on SEC EDGAR

View on Read The Filing